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Multidrug-resistant organisms (MDROs) such as methicillin-resistant Staphylococcus 
aureus, vancomycin-resistant enterococci, carbapenem-resistant Enterobacateriaceae, and 
Clostridium difficile all share certain epidemiologic characteristics: transmission via direct 
and indirect contact, colonization preceding infection by days to months, and a greater 
number of asymptomatically colonized than infected patients. For each of these MDROs, 
colonized patients may serve as an important source for healthcare transmission. Active 
surveillance (AS) to identify colonized patients has been used to prevent the transmission of 
MDROs by focusing isolation and/or decolonization efforts. In the case of C. difficile 
infection (CDI), AS has not been attempted largely because there has not been a feasible 
method for detecting colonized patients and the role of colonized patients in overall 
transmission has not been well defined. In this issue, Curry et al. cast additional light on the 
role of asymptomatic colonization in C. difficile transmission leading to hospital-associated 
CDI (HA-CDI: defined as hospital-onset cases plus community-onset within 12 weeks of 
previous discharge and no intervening hospital stay).[1, 2]
First, an important incidental finding was that among 114 AS cultures performed on patients 
8 or more days before their first positive toxin assay (when they were symptomatic), 10 
cultures from 7 patients were positive for isolates highly related to the isolate recovered later 
from the patient’s first toxin-positive stool. Previous studies suggest incubation periods less 
than 3–7 days and the prevailing disease model is one that sustained asymptomatic 
colonization paradoxically reduces patient’s risk for subsequent CDI through boosting of 
serum antibodies to toxins A and B.[3–6] Although intriguing, this finding by Curry et al. 
does not necessarily challenge that model nor is it sufficient to provoke revision in current 
surveillance definitions.[2] The total number of patients in whom the prior cultures were 
performed was not reported; however, assuming a similar ratio of cultures to patients (i.e. 
10:7) for all 114, less than 10% of evaluable CDI patients had incubation periods over 7 
days--possibly representing the ‘trailing off’ of a skewed normal distribution of incubation 
periods with a median less than 3 days and a somewhat larger mean.
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The main conclusion of the report by Curry et al., namely that at least 29% of HA-CDI 
results from transmission from asymptomatic carriers, is sensitive to several important 
factors. First, the study setting was a tertiary hospital with a seasoned infection control 
program focused on containing transmission from CDI patients. An average rate of 5.6 HA-
CDI cases/10,000 patient days (2006–12) supports the assertion of an effective program at 
interrupting transmission from CDI cases,[7] especially given the hospitals tertiary care 
status with intensive antibiotic exposures. Hospitals with less effective infection control 
would have a higher proportion of all cases resulting from transmission from CDI patients.
A recent study in England found only about 25% of CDI cases result from ward-based 
transmission from a prior CDI patient.[8] However, that result was limited by the use of a 
toxin A and B enzyme immunonassay (EIA) as the diagnostic assay. Although the cell 
cytotoxin neutralization assay used by Curry et al. is more sensitive than an EIA, it is still 
less sensitive than a nucleic acid amplification test (NAAT). Because of its increased 
sensitivity, it is likely that use of a NAAT for diagnosis would result in a higher proportion 
of CDIs linked to previous NAAT-defined CDIs.
In contrast, more extensive and comprehensive AS testing would increase the proportion of 
CDIs traced to previously colonized patients. Use of swabs collected for vancomycin-
resistant enterococcus screening was an efficient use of resources by Curry et al. but only 
24.9% of all admissions during the 117-day study period were screened for asymptomatic 
carriage.[1] Had a larger proportion of all inpatients, including those with more CDI-
directed risk factors (e.g. patients >65 y.o. readmitted from home or nursing home after a 
recent inpatient stay in which antibiotics were administered) been subjected to AS, a larger 
number of colonized patients would have been identified and likely a larger proportion of all 
CDIs would have been linked back to colonized patients.
Even where 29% or more of new HA-CDI cases are confirmed to be the result of 
transmission from colonized patients, there are several hurdles to overcome before AS can 
be used in CDI prevention. First is the need to rapidly detect colonization. Although Curry et 
al. previously demonstrated accurate detection of colonization through use of a broth 
amplification culture followed by commercial NAAT, the pre-amplification incubation could 
last as long as 72 hours, calling into question the utility of the approach.[9] While existing 
commercial diagnostics could be refined or new ones developed to improve the rapid, 
sensitive detection of nearly all colonized patients, currently available NAATs may serve a 
useful purpose even without broth pre-amplification. For example, currently available 
NAATs alone may reliably detect a subset of colonized patients with higher organism loads 
who are more contagious as reflected by skin and environmental contamination.
Once colonized patients are identified, special precautions will be needed to reduce 
transmission from these patients to other susceptible patients. In the case of other MDROs 
this has most commonly entailed isolating colonized patients using Contact Precautions. 
However, criticism has been leveled at AS partly for this reason.[10] It may be more cost 
effective to apply broad, ‘horizontal’ approaches to prevent all MDROs and healthcare-
associated infections, such as improved hand hygiene for all patients, over a more 
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burdensome ‘vertical’ approach such AS-directed isolation of all specific MDRO-colonized 
patients.
However, because of its uniqueness as a spore-forming cause of healthcare-associated 
infection, AS-directed special precautions may have particular relevance for C. difficile 
compared to other MDROs. For example, enhanced cleaning with a C. difficile sporicidal 
disinfectant and the use of gloves for patient care are more efficacious than standard 
methods at reducing environmental and hand contamination, respectively.[11–13] Thus one 
approach would be to perform enhanced environmental cleaning, possibly along with the use 
of gloves for all patient care, for patients colonized with C. difficile.
It also appears that limiting colonized patient movement, or at least employing enhanced 
precautions and cleaning when a colonized patient does need to go to non-ward locations, 
may be another key strategy. Whether linked to a prior colonized or infected patient, 
transmission frequently occurs across different ward locations.[1, 8] Although some of this 
may reflect carriage of C. difficile spores from ward to ward by either contaminated hands 
of healthcare personnel or contaminated reusable medical equipment, cross transmission 
may be occurring frequently, especially from those asymptomatically colonized, in non-ward 
locations (e.g. emergency departments, physical therapy, or diagnostic imaging).
Even if its spore-forming status strengthens the case for using a vertical approach of AS-
focused precautions to reduce C. difficile transmission, there are several special horizontal 
approaches to consider. One possible approach on particular ward locations with high rates 
of colonization and infection is universal gloving along with enhanced cleaning and 
environmental disinfection. Perhaps in the future, improved hand hygiene and environmental 
disinfection products can be developed that better remove or deactivate spores and yet can 
be used more broadly. Regardless, another important horizontal approach, the importance of 
which cannot be overstated, is antibiotic stewardship. Because reducing unnecessary 
antibiotic exposures decreases the risk of colonization and infection by a number of 
MDROs, especially CDI, a highly effective stewardship intervention could easily 
overshadow the impact of further reducing C. difficile transmission through AS-focused 
measures.[14] A third possible horizontal approach with rapidly broadening evidence base in 
the prevention of CDI is the use of probiotics in patients receiving antibiotics.[15, 16] 
However, thus far there is not a similar level of evidence for probiotics preventing 
colonization or infection from MDROs other than C. difficile.
Regardless of what becomes the future role for vertical vs. horizontal measures to reduce 
CDI, Curry et al. have done a good job highlighting the importance of better understanding 
the epidemiology of C. difficile colonization and infection in healthcare settings.
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